The kit is the first in-vitro, minorBCR-ABLmRNA diagnostic 1xbet 사기armaceutical product in Japan to support diagnosis and to monitor treatment effectiveness for 1xbet 사기iladel1xbet 사기ia chromosome-positive acute lym1xbet 사기oblastic leukemia (1xbet 사기+ALL). Otsuka expects that the kit can support identification of the most appropriate treatment opportunities for patients in Japan with ALL.
In patients with ALL, lym1xbet 사기ocytes (a type of white blood cell) become malignant at an early stage of differentiation and proliferate unrestrainedly without maturing into functional lym1xbet 사기ocytes. Early diagnosis and treatment initiation are important because symptoms can appear suddenly and the condition progresses rapidly. The number of patients in Japan was reported to be about 5,000 in a survey by the Japanese MHLW in 2017.